VXRT - Vaxart, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.7200
-0.0019 (-0.26%)
As of 11:26AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.7219
Open0.7000
Bid0.7000 x 3200
Ask0.7200 x 2200
Day's Range0.6900 - 0.7200
52 Week Range0.6000 - 7.6000
Volume15,221
Avg. Volume403,350
Market Cap11.341M
Beta (3Y Monthly)0.75
PE Ratio (TTM)N/A
EPS (TTM)-3.0770
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2012-11-09
1y Target Est2.00
Trade prices are not sourced from all markets
  • Business Wire7 days ago

    Vaxart Enters into Research Collaboration with Janssen to Evaluate Oral Universal Influenza Vaccine

    Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate Vaxart’s proprietary oral vaccine platform for the Janssen universal influenza vaccine program.

  • Business Wire26 days ago

    Vaxart to Present at ASM Microbe 2019

    Vaxart, Inc. , a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.D., senior scientist at Vaxart, will present preclinical results of its oral Respiratory Syncytial Virus vaccine in a poster presentation at the American Society of Microbiology 2019, taking place from June 20-24, ...

  • Business Wire2 months ago

    New Publication in Vaccine Highlights Preclinical Results of Vaxart’s Mucosal Chikungunya Vaccine

    Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the publication of the comprehensive results from a preclinical trial of its chikungunya vaccine in the peer reviewed journal, Vaccine. The article, titled “An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling,” details the results from a study using Vaxart’s chikungunya vaccine candidate in a preclinical efficacy model. “These preclinical results demonstrate that our vaccine candidate induced significant neutralizing antibodies against chikungunya virus as well as protective efficacy against virus-induced pathologic changes,” said Sean Tucker, Ph.D., founder and chief scientific officer of Vaxart.

  • Business Wire2 months ago

    Vaxart Announces First Quarter 2019 Financial Results and Provides Corporate Update

    - $13 million raised in 1H19 -

  • Have Insiders Been Buying Vaxart, Inc. (NASDAQ:VXRT) Shares?
    Simply Wall St.2 months ago

    Have Insiders Been Buying Vaxart, Inc. (NASDAQ:VXRT) Shares?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We often see insiders buying up shares in companies that perform well over the long term. The flip side...

  • Business Wire3 months ago

    Vaxart Doses First Patient in Randomized Cohort of Bivalent Norovirus Vaccine Phase 1b Clinical Trial

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced it has started dosing subjects in the randomized cohort of the Phase 1b bivalent norovirus vaccine clinical trial. “We are delighted to start the randomized portion of the bivalent norovirus phase 1b trial,” said David Taylor, M.D., chief medical officer of Vaxart. Norovirus is the leading cause of foodborne illness in the United States and causes significant morbidity and mortality in older adults and the very young.

  • Business Wire3 months ago

    Vaxart to Present at the 29th European Congress of Clinical Microbiology & Infectious Diseases

    Vaxart, Inc. (VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.D., lead scientist at Vaxart, will present preclinical data in a poster presentation at the 29th European Congress of Clinical Microbiology and Infectious Diseases showing that Vaxart’s oral quadrivalent influenza vaccine conferred 100% protection against a lethal H5N1 avian influenza challenge in ferrets.

  • Business Wire3 months ago

    Vaxart Announces Pricing of Underwritten Public Offering

    Vaxart, Inc. (VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced the pricing of an underwritten public offering of 9,090,010 shares of common stock (which includes pre-funded warrants to purchase up to an aggregate of 8,165,455 shares of common stock in lieu thereof), and common warrants to purchase up to an aggregate of 9,090,010 shares of common stock. Each share of common stock and, as applicable, pre-funded warrant is being sold together with a common warrant to purchase one share of common stock at an effective price to the public of $1.10 per share and accompanying common warrant. Each common warrant will have an exercise price of $1.10 per share, be exercisable immediately and will expire five years from the date of issuance.

  • Business Wire4 months ago

    Vaxart to Present at Global Medical Meetings in April

    Vaxart, Inc. (VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced participation in two upcoming global medical meetings in April.

  • Business Wire4 months ago

    Vaxart Completes Dosing of the Lead-In Cohort in Bivalent Norovirus Vaccine Phase 1b Clinical Trial

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the completion of dosing of the lead-in cohort in the Phase 1b bivalent norovirus vaccine clinical trial with its oral norovirus GII.4 vaccine. The Vaxart bivalent norovirus vaccine consists of an oral norovirus GI.1 vaccine and an oral norovirus GII.4 vaccine administered concurrently by tablet. The bivalent norovirus Phase 1b trial consists of two parts, an open-label lead-in phase which has now been completed, and a randomized, double-blind, placebo-controlled phase which is expected to start in April, subject to final review by the FDA.

  • Business Wire4 months ago

    Vaxart Announces Closing of Registered Direct Offering of Common Stock

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the closing of its previously announced registered direct offering of 1,200,000 shares of its common stock at a price of $2.50 per share. Total gross proceeds from the offering were $3.0 million, before deducting placement agent fees and estimated offering expenses. The securities described above were offered by Vaxart pursuant to a registration statement on Form S-3 (File No. 333-228910) previously filed with and subsequently declared effective by the Securities and Exchange Commission (SEC) on March 15, 2019.

  • ACCESSWIRE4 months ago

    Watch These Four Healthcare Stocks Set The Pace On Tuesday

    Recently, we've seen healthcare companies demonstrate their collective abilities to meet the growing challenges presented by infectious diseases and ailments, with innovative treatment options and medical technologies. Premier Health Group (PHGRF) (PHGI), Vaxart Inc (VXRT), BioPharmX Corporation (NYSE American: BPMX), and Trevena Inc (TRVN) are 4 healthcare companies worth looking into on Tuesday. Premier Health will be partnering with BCT to enable patients and care providers improved monitoring of chronic disease progression and management of chronic conditions, such as diabetes, using BCT's proprietary AI technology.

  • Business Wire4 months ago

    Vaxart Announces $3 Million Registered Direct Offering Priced At-the-Market

    Vaxart, Inc. (VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale in a registered direct offering priced at-the-market of 1,200,000 shares of the Vaxart’s common stock, at a purchase price of $2.50 per share, for aggregate gross proceeds of $3 million. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering. The shares of common stock are being offered by Vaxart pursuant to a “shelf” registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC").

  • Business Wire4 months ago

    Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the initiation of a Phase 1b bivalent norovirus vaccine clinical trial. “The initiation of the bivalent norovirus vaccine Phase 1b trial marks a significant step towards our goal of developing a vaccine that can protect the most vulnerable patients from this highly infectious disease,” said Wouter Latour, M.D., chief executive officer of Vaxart.

  • Business Wire5 months ago

    Vaxart Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update

    Initiation of Two Norovirus Vaccine Trials Expected in 1H 2019

  • Business Wire8 months ago

    Vaxart to Present at World Vaccine and Immunotherapy Congress West Coast 2018

    Vaxart, Inc. (VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Sean Tucker, Ph.D., chief scientific officer, will present summary data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at the World Vaccine and Immunotherapy Congress West Coast 2018, taking place from November 28-30, 2018 in San Diego, California. Vaxart received a $13.9 million contract from BARDA in September 2015 to support the advanced development of more effective influenza vaccines to ultimately improve seasonal and pandemic influenza preparedness.

  • Business Wire8 months ago

    Vaxart Announces Third Quarter 2018 Financial Results and Provides Corporate Update

    Start of Norovirus Vaccine Trials Delayed to 1H 2019 Due to Manufacturing Issue

  • InvestorPlace9 months ago

    Vaxart’s Flu Vaccine Looks Promising, But Its Future Is Uncertain

    Just look at biotech company Vaxart (NASDAQ:VXRT), whose shares soared by a sizzling 78% to $5.25. Of course, the company got some favorable news from one of its clinical trials. In a Phase 2 study, patients taking its H1 influenza vaccine showed a 39% reduction in illness compared to those taking a placebo.

  • Vaxart's Flu Vaccine Superior to Sanofi's Fluzone, Shares Up
    Zacks9 months ago

    Vaxart's Flu Vaccine Superior to Sanofi's Fluzone, Shares Up

    Vaxart's (VXRT) oral flu vaccine candidate achieves 39% reduction in flu illness compared to 27% for market leader, Sanofi's Fluzone.

  • ACCESSWIRE9 months ago

    Today’s Research Reports on Stocks to Watch: Guardant Health and Vaxart

    NEW YORK, NY / ACCESSWIRE / October 5, 2018 / Shares of Guardant Health made a staggering debut in the market on Thursday. The cancer detecting company closed up nearly 70% as it debuted on the NASDAQ. Shares of Vaxart Inc. also saw huge gains on news that its oral flu vaccine performed better than Sanofi's Fluzone in a phase 2 trial.

  • Business Wire9 months ago

    New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart’s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced it will present new data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at IDWeek 2018 in San Francisco on Saturday, October 6, 2018. “These latest results show that our vaccine elicited a significant expansion of mucosal homing receptor α4β7+ (β7+) plasmablasts to approximately 60% of all activated B cells, while Fluzone only maintained baseline levels of 20%.

  • Business Wire11 months ago

    Vaxart Announces Second Quarter 2018 Financial Results and Corporate Update

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the second quarter ended June 30, 2018 and provided a corporate update.